The tweet was deleted by the author.
But we saved everything 🙂.
Eyepoint Pharmaceuticals has announced the completion of patient enrollment in both pivotal Phase 3 clinical trials of its investigational therapy DURAVYU for diabetic macular edema (DME).
The company stated that topline results from these trials are anticipated in the fourth quarter of 2027, marking a significant milestone in the development of its potential ophthalmic treatment. Further updates on DURAVYU’s progress are expected as the trial results approach.
View post on X Loading...
Eyepoint Pharmaceuticals recently participated in the Montreal ASRS annual meeting to discuss collaboration and innovation in retina treatment, according to a previous company update. The firm also appointed Tarek S Hassan as chief strategic science officer ahead of Phase 3 results for wet age-related macular degeneration, as detailed in an earlier announcement. These developments reflect the company's ongoing efforts to advance its position in ophthalmic therapeutics.